is hers going to stop selling semaglutide The era of $199 copycat weight loss drugs ending — and it could cost patients Novo Nordisk, Hims & Hers
Description
Source: U.S
That is a feature not a bug
& Tauber M
Moreover, public health efforts that encourage the use of GLP-1 therapies, alongside growing awareness and access to branded semaglutide products, are further expanding the regional share of the industry
Australia's TGA has not reviewed or approved retatrutide
Various parameters like weight loss, change in BMI, FPG, HbA1c, number of adverse events have been studied
